Market Closed -
Nasdaq
21:30:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
3.05
USD
|
-1.61%
|
|
-6.15%
|
-47.41%
|
Fiscal Period: Giugno |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
178.2
|
437.8
|
320.9
|
80.56
|
43.84
|
20.32
|
-
|
-
|
Enterprise Value (EV)
1 |
178.2
|
425.4
|
320.9
|
80.56
|
43.84
|
20.32
|
20.32
|
20.32
|
P/E ratio
|
-10.4
x
|
-8.1
x
|
-6.33
x
|
-1.38
x
|
-1.38
x
|
0.93
x
|
-0.52
x
|
-0.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
36.3
x
|
15.1
x
|
12.6
x
|
1.98
x
|
0.9
x
|
0.31
x
|
3.25
x
|
0.81
x
|
EV / Revenue
|
36.3
x
|
15.1
x
|
12.6
x
|
1.98
x
|
0.9
x
|
0.31
x
|
3.25
x
|
0.81
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-6,013,028
x
|
13,121,162
x
|
-9,821,453
x
|
-1,636,506
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
7.76
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,565
|
5,300
|
5,630
|
6,658
|
6,663
|
6,663
|
-
|
-
|
Reference price
2 |
50.00
|
82.60
|
57.00
|
12.10
|
6.580
|
3.050
|
3.050
|
3.050
|
Announcement Date
|
28/08/19
|
09/09/20
|
02/09/21
|
08/09/22
|
26/09/23
|
-
|
-
|
-
|
Fiscal Period: Giugno |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.915
|
28.91
|
25.54
|
40.7
|
48.82
|
65.38
|
6.25
|
25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-46.24
|
-24.54
|
-69.68
|
-75.48
|
-36.76
|
20.87
|
-42.32
|
-28.34
|
Operating Margin
|
-940.9%
|
-84.88%
|
-272.9%
|
-185.48%
|
-75.31%
|
31.92%
|
-677.1%
|
-113.36%
|
Earnings before Tax (EBT)
1 |
-16.82
|
-46.02
|
-50.57
|
-54.45
|
-31.84
|
24.41
|
-41.28
|
-24.83
|
Net income
1 |
-16.82
|
-46.02
|
-50.58
|
-54.45
|
-31.84
|
24.41
|
-41.28
|
-24.83
|
Net margin
|
-342.2%
|
-159.15%
|
-198.06%
|
-133.8%
|
-65.22%
|
37.33%
|
-660.48%
|
-99.31%
|
EPS
2 |
-4.800
|
-10.20
|
-9.000
|
-8.800
|
-4.780
|
3.285
|
-5.850
|
-3.550
|
Free Cash Flow
|
-29.64
|
33.36
|
-32.67
|
-49.22
|
-
|
-
|
-
|
-
|
FCF margin
|
-603.05%
|
115.39%
|
-127.95%
|
-120.95%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/08/19
|
09/09/20
|
02/09/21
|
08/09/22
|
26/09/23
|
-
|
-
|
-
|
Fiscal Period: Juni |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
13.39
|
18.22
|
9.694
|
11.41
|
8.73
|
32.74
|
5.894
|
1.457
|
65.3
|
-
|
0.025
|
0.0333
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.48
|
-11.24
|
-21.56
|
-16.2
|
-18.22
|
8.926
|
-16.39
|
-11.08
|
55.28
|
-11.93
|
-11.49
|
-12.23
|
-14.2
|
-14.9
|
Operating Margin
|
-108.13%
|
-61.66%
|
-222.38%
|
-141.9%
|
-208.69%
|
27.27%
|
-278.1%
|
-760.47%
|
84.66%
|
-
|
-45,970.68%
|
-36,682.66%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.88
|
-5.766
|
-8.725
|
-16.06
|
-16.62
|
10.25
|
-15.44
|
-10.03
|
56.37
|
-11.06
|
-10.74
|
-11.49
|
-13.6
|
-14.3
|
Net income
1 |
-11.88
|
-5.766
|
-8.725
|
-16.06
|
-16.62
|
10.25
|
-15.44
|
-10.03
|
56.37
|
-11.06
|
-9.942
|
-10.63
|
-10.9
|
-11.5
|
Net margin
|
-88.74%
|
-31.64%
|
-90%
|
-140.73%
|
-190.42%
|
31.32%
|
-261.93%
|
-688.33%
|
86.33%
|
-
|
-39,769.32%
|
-31,880.2%
|
-
|
-
|
EPS
2 |
-2.200
|
-1.000
|
-1.400
|
-2.400
|
-2.400
|
1.600
|
-2.320
|
-1.507
|
8.460
|
-1.660
|
-1.487
|
-1.580
|
-1.640
|
-1.720
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
10/02/22
|
23/05/22
|
08/09/22
|
14/11/22
|
09/02/23
|
11/05/23
|
26/09/23
|
09/11/23
|
13/02/24
|
-
|
-
|
-
|
-
|
Fiscal Period: Juni |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
12.3
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-29.6
|
33.4
|
-32.7
|
-49.2
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-26.4%
|
-
|
-22.4%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
191.9
|
-
|
142.2
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
7.350
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-7.880
|
-
|
-
|
-
|
Capex
|
0.22
|
0.89
|
0.71
|
0.48
|
-
|
-
|
-
|
-
|
Capex / Sales
|
4.42%
|
3.09%
|
2.77%
|
1.18%
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/08/19
|
09/09/20
|
02/09/21
|
08/09/22
|
26/09/23
|
-
|
-
|
-
|
Last Close Price
3.05
USD Average target price
23
USD Spread / Average Target +654.10% Consensus |
1st Jan change
|
Capi.
|
---|
| -47.41% | 20.32M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|